What is the Prostate-Specific Antigen Cut-Off Value to Detect Clinically Significant Prostate Cancer According to Age in Turkey?
Yıl: 2018 Cilt: 17 Sayı: 2 Sayfa Aralığı: 49 - 53 Metin Dili: İngilizce DOI: 10.4274/uob.970 İndeks Tarihi: 23-09-2019
What is the Prostate-Specific Antigen Cut-Off Value to Detect Clinically Significant Prostate Cancer According to Age in Turkey?
Öz: Objective: To detect a prostate-specific antigen (PSA) cut-off for clinically significant prostate cancer (csPCa) according to age in Turkey.Materials and Methods: A total of 532 men who had transrectal ultrasound-guided biopsy of the prostate due to elevated PSA and abnormal findingson digital rectal examination between January 2011 and January 2018 were retrospectively evaluated. Elevated PSA was defined as ≥4 ng/mL. Patientswere divided into groups 1-5 according to age: 40-49, 50-59, 60-69, 70-79, and ≥80 years. A PSA cut-off value was determined for each group.Results: The mean age was 66.45±8.21 (41-89) years. There were 20, 112, 222, 154, and 24 patients in groups 1-5, respectively. Mean PSAvalues were 6.04±3.88 (0.24-16.46) ng/mL, 6.8±4.17 (0.97-35.07) ng/mL, 10.51±8.53 (0.72-128.5) ng/mL, 20.41±36.64 (1.32-250) ng/mL, and73.28±100.19 (9.33-344.1) ng/mL in groups 1-5, respectively. PSA cut-off values for csPCa were 7.08 ng/mL, 4.71 ng/mL, 7.30 ng/mL, 8.12 ng/mL,and 14.12 ng/mL in groups 1-5, respectively.Conclusion: There is a correlation between PSA and age in Turkey. Using the PSA cut-off values determined in our study would decrease the numberof unnecessary biopsy procedures.
Anahtar Kelime: Konular:
Türkiye’de Klinik Önemli Prostat Kanseri Saptamada Yaşa Göre Prostat Spesifik Antijen Eşik Değerleri Ne Olmalıdır?
Öz: Amaç: Türkiye’de klinik önemli prostat kanseri (KÖPK) saptanmasında kullanılabilecek yaşa göre prostat spesifik antijen (PSA) eşik değerlerini saptamayı amaçladık. Gereç ve Yöntem: Ocak 2011 ile Ocak 2018 yılları arasında PSA yüksekliği tespit edilmiş veya parmakla rektal muayenede anormal bulgular saptanmış ve sonrasında transrektal ultrason prostat biyopsisi uygulanmış 532 hastanın verileri retrospektif olarak değerlendirildi. PSA yüksekliği tanımı “PSA ≥4 ng/mL” olarak belirlendi. Hastalar yaş grubuna göre; grup 1: 40-49 yaş arası, grup 2: 50-59 yaş arası, grup 3: 60-69 yaş arası, grup 4: 70-79 yaş arası ve grup 5: ≥80 yaş üstü olarak sınıflandırıldı. Belirlenen gruplardaki KÖPK saptanması için PSA eşik değerleri belirlendi. Bulgular: Hastaların ortalama yaşı 66,45±8,21 yıl (41-89) olarak tespit edildi. Grup 1, 2, 3, 4 ve 5’te sırası ile 20, 112, 222, 154 ve 24 hasta mevcut idi. Grup 1, 2, 3, 4 ve 5’te ortalama PSA değerleri sırası ile 6,04±3,88 (0,24-16,46) ng/mL, 6,8±4,17 (0,97-35,07) ng/mL, 10,51±8,53 (0,72-128,5) ng/mL, 20,41±36,64 (1,32-250) ng/mL ve 73,28±100,19 (9,33-344,1) ng/mL olarak tespit edildi. Grup 1, 2, 3, 4 ve 5’te KÖPK saptanmasındaki PSA eşik değerleri 7,08 ng/mL, 4,71 ng/mL, 7,30 ng/mL, 8,12 ng/ml ve 14,12 ng/mL olarak saptandı. Sonuç: Türkiye’de PSA değeri yaş ile artış göstermektedir ve KÖPK saptanması için belirttiğimiz PSA eşik değerlerinin kullanılması gereksiz biyopsileri önleyebilecektir.
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostatespecific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-1161.
- Nogueira L, Corradi R, Eastham JA. Other biomarkers for detecting prostate cancer. BJU Int 2011;105:166-169.
- Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostatecancer mortality in a randomized European study. N Engl J Med 2009;26;360:1320-1328.
- Andriole GL, Crawford ED, Grubb RL 3rd, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;26;360:1310-1319.
- Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014;6;384:2027-2035.
- Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostatespecific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993;18;270:860-864.
- Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994;151:1283-1290.
- Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998;20;279:1542-1547.
- Loeb S, Gonzalez CM, Roehl KA, et al. Pathological characteristics of prostate cancer detected through prostate specific antigen based screening. J Urol 2006;175:902-906.
- Siddiqui MM, Rais-Bahrami S, Turkbey B, et al. Comparison of MR/ ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA 2015;27;313:390-397.
- Wang R, Chinnaivan AM, Dunn RL, et al. Rational approach to implementation of prostate cancer antigen 3 clinical care. Cancer 2009;115:3879-3886.
- Ma Q, Yang DR, Xue BX, et al. Transrectal real-time tissue elastography targeted biopsy coupled with peak strain index improvest the detection of clinically important prostate cancer. Oncol Lett 2017;14:210-216.
- Lee JG, Bae SH, Choi SH, et al. Role of prostate-specific antigen ratio initial biopsy as a novel decision making marker repeat prostate biopsy. Korean J Urol 2012;53:467-471.
| APA | EBILOGLU T, kaya e (2018). What is the Prostate-Specific Antigen Cut-Off Value to Detect Clinically Significant Prostate Cancer According to Age in Turkey?. , 49 - 53. 10.4274/uob.970 |
| Chicago | EBILOGLU Turgay,kaya engin What is the Prostate-Specific Antigen Cut-Off Value to Detect Clinically Significant Prostate Cancer According to Age in Turkey?. (2018): 49 - 53. 10.4274/uob.970 |
| MLA | EBILOGLU Turgay,kaya engin What is the Prostate-Specific Antigen Cut-Off Value to Detect Clinically Significant Prostate Cancer According to Age in Turkey?. , 2018, ss.49 - 53. 10.4274/uob.970 |
| AMA | EBILOGLU T,kaya e What is the Prostate-Specific Antigen Cut-Off Value to Detect Clinically Significant Prostate Cancer According to Age in Turkey?. . 2018; 49 - 53. 10.4274/uob.970 |
| Vancouver | EBILOGLU T,kaya e What is the Prostate-Specific Antigen Cut-Off Value to Detect Clinically Significant Prostate Cancer According to Age in Turkey?. . 2018; 49 - 53. 10.4274/uob.970 |
| IEEE | EBILOGLU T,kaya e "What is the Prostate-Specific Antigen Cut-Off Value to Detect Clinically Significant Prostate Cancer According to Age in Turkey?." , ss.49 - 53, 2018. 10.4274/uob.970 |
| ISNAD | EBILOGLU, Turgay - kaya, engin. "What is the Prostate-Specific Antigen Cut-Off Value to Detect Clinically Significant Prostate Cancer According to Age in Turkey?". (2018), 49-53. https://doi.org/10.4274/uob.970 |
| APA | EBILOGLU T, kaya e (2018). What is the Prostate-Specific Antigen Cut-Off Value to Detect Clinically Significant Prostate Cancer According to Age in Turkey?. Üroonkoloji Bülteni, 17(2), 49 - 53. 10.4274/uob.970 |
| Chicago | EBILOGLU Turgay,kaya engin What is the Prostate-Specific Antigen Cut-Off Value to Detect Clinically Significant Prostate Cancer According to Age in Turkey?. Üroonkoloji Bülteni 17, no.2 (2018): 49 - 53. 10.4274/uob.970 |
| MLA | EBILOGLU Turgay,kaya engin What is the Prostate-Specific Antigen Cut-Off Value to Detect Clinically Significant Prostate Cancer According to Age in Turkey?. Üroonkoloji Bülteni, vol.17, no.2, 2018, ss.49 - 53. 10.4274/uob.970 |
| AMA | EBILOGLU T,kaya e What is the Prostate-Specific Antigen Cut-Off Value to Detect Clinically Significant Prostate Cancer According to Age in Turkey?. Üroonkoloji Bülteni. 2018; 17(2): 49 - 53. 10.4274/uob.970 |
| Vancouver | EBILOGLU T,kaya e What is the Prostate-Specific Antigen Cut-Off Value to Detect Clinically Significant Prostate Cancer According to Age in Turkey?. Üroonkoloji Bülteni. 2018; 17(2): 49 - 53. 10.4274/uob.970 |
| IEEE | EBILOGLU T,kaya e "What is the Prostate-Specific Antigen Cut-Off Value to Detect Clinically Significant Prostate Cancer According to Age in Turkey?." Üroonkoloji Bülteni, 17, ss.49 - 53, 2018. 10.4274/uob.970 |
| ISNAD | EBILOGLU, Turgay - kaya, engin. "What is the Prostate-Specific Antigen Cut-Off Value to Detect Clinically Significant Prostate Cancer According to Age in Turkey?". Üroonkoloji Bülteni 17/2 (2018), 49-53. https://doi.org/10.4274/uob.970 |
